资讯
Eli Lilly (NYSE:LLY) recently received FDA approval for a new dosing schedule of Kisunla, aimed at reducing amyloid-related ...
Eli Lilly and Company (NYSE:LLY) is one of Goldman Sachs’ top healthcare stock picks. On July 9, the company confirmed the ...
9 天
Stocktwits on MSNEli Lilly’s Alzheimer’s Drug Gets US FDA Label Update For More Gradual Dosing After ...Eli Lilly and Company (LLY) announced on Wednesday that the U.S. Food and Drug Administration (FDA) has approved a label ...
The benefit-risk balance is tipping more in favor of Eli Lilly’s Kisunla in early Alzheimer’s disease as the FDA ...
Eli Lilly has won a green light from the FDA for new dosing for its Alzheimer's disease therapy Kisunla, which carries a ...
The FDA will allow a new dosing schedule for Eli Lilly’s Alzheimer’s drug Kisunla that could lessen a known side effect of ...
The U.S. Food and Drug Administration approved changing the prescribing information for Eli Lilly's Alzheimer's drug Kisunla to allow more gradual dosing to lower the risk of a potentially dangerous ...
NICE said it made every effort to support reimbursement for Kisunla and Leqembi, but found the medicines are “not good value for money”.
Eli Lilly (LLY) stock in focus as the company wins FDA approval for a label update for its Alzheimer's drug, Kisunla. Read more here.
Lilly's Kisunla gets FDA approval for a new dosing schedule that significantly lowers ARIA-E risk while maintaining amyloid ...
The US Food and Drug Administration (FDA) has approved a label update with a new recommended titration dosing schedule for ...
A slower ramp-up of Kisunla dosing lowers the rate of dangerous brain swelling, a risk that has made doctors reluctant to ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果